Pom-resistant PEL cells have decreased expression of cereblon. حسب Prabha Shrestha (776391)

Viral replication in obese mice results in decreased genetic diversity. حسب James Weger-Lucarelli (603766)

Study Flow Diagram. حسب Elizabeth S. Munroe (21568166)

CPSF6 protein expression is decreased in virus-infected cells. حسب Yong Ge (816832)

Antibody and antigen responses to nMAb vs placebo day 1–90 for Amubarvimab/ Romlusevimab. حسب Elizabeth S. Munroe (21568166)

Antibody and antigen responses to Ensovibep vs placebo day 1–90. حسب Elizabeth S. Munroe (21568166)

Antibody and antigen responses to nMAb vs placebo day 1–90 for Tixagevimab/ Cilgavimab. حسب Elizabeth S. Munroe (21568166)

Antibody and antigen responses to nMAb vs placebo day 1–90 for Bamlanivimab. حسب Elizabeth S. Munroe (21568166)

Antibody and antigen responses to nMAb vs placebo day 1–90 for Sotrovimab. حسب Elizabeth S. Munroe (21568166)

Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for nMAbs, among patients alive and with day 90 antibody and antigen measures (Sensitivity Analysis). حسب Elizabeth S. Munroe (21568166)

Long-term anti-nucleocapsid response by baseline patient characteristics. حسب Elizabeth S. Munroe (21568166)

Antibody and antigen responses to Lufotrelvir vs placebo day 1–90. حسب Elizabeth S. Munroe (21568166)

Antibody and antigen responses by baseline anti-spike neutralizing response assay positivity. حسب Elizabeth S. Munroe (21568166)

Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for neutralizing monoclonal antibodies, among patients alive and with day 90 antibody and antigen measu... حسب Elizabeth S. Munroe (21568166)

Antibody and antigen responses after treatment with nMAb vs placebo, day 1-90 (pooled nMAb treatments). حسب Elizabeth S. Munroe (21568166)

Baseline patient characteristics across neutralizing monoclonal antibody trials. حسب Elizabeth S. Munroe (21568166)

Quantitative antibody and antigen responses to nMAb vs placebo day 1-90: Pooled analysis of neutralizing monoclonal antibodies. حسب Elizabeth S. Munroe (21568166)

Drug-induced decrease of cell anisotropy reduces pattern fidelity. حسب Camille Curantz (7456499)

"…The data underlying this figure can be found at 10.5281/zenodo.7006365. Error bars: mean with standard deviation; significance of statistical tests for anisotropy amplitude is shown with stars. …"

Study selection criteria. حسب Filip Stanicic (17808254)

"…CAPS improvement was persistent for CPT and PE in long-term follow up (mean duration 6.2 years).</p><p>MDMA-AT demonstrated significant improvement in BDI-II score compared to PT (19.7-point vs. 10.8-point decrease, respectively; p = 0.003). …"

PICOS criteria for the SLR. حسب Filip Stanicic (17808254)

"…CAPS improvement was persistent for CPT and PE in long-term follow up (mean duration 6.2 years).</p><p>MDMA-AT demonstrated significant improvement in BDI-II score compared to PT (19.7-point vs. 10.8-point decrease, respectively; p = 0.003). …"